JZHT(HK) Capital Services limited Mediaroom - PR Newswire APAC

Search

JZHT(HK) Capital Services limited

Latest News

AIM Vaccine Forecasts Surge in Stock Performance: Innovations Reinforce Leadership in Vaccine Sector

HONG KONG, Aug. 28, 2025 /PRNewswire/ -- AIM Vaccine (06660.HK), a leading domestic vaccine company...

2025-08-28 07:45 1318

AIM Vaccine's Next-Gen mRNA Shingles Vaccine Secures Clinical Approvals in Both PRC and U.S. ,mRNA Platform Advantages Shine Through

HONG KONG, May 19, 2025 /PRNewswire/ -- While global giants like Moderna and BioNTech apply mRNA te...

2025-05-19 08:30 2976

AIM's Serum-Free Iterative Rabies Vaccine Receives Acceptance for Market Registration; Institutions Predict Significant Valuation Recovery Potential for the Company

HONG KONG, April 8, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine co...

2025-04-08 08:00 2289

AIM Vaccine reduces losses by nearly 90% in 2024, with the iterative major product series opening up space for explosive growth in performance

HONG KONG, March 31, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine c...

2025-03-31 08:00 3104

AIM Vaccine's mRNA Shingles Vaccine Approved by the US FDA to Begin Clinical Trials, AI-Enabled mRNA Major Vaccine Product Development Accelerates

HONG KONG, March 24, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine c...

2025-03-24 08:00 2069

AIM Vaccine reported a significant reduction in losses for 2024, with several major products set to launch that are expected to drive substantial revenue growth

HONG KONG, March 17, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine c...

2025-03-17 14:30 3221

AIM Vaccine's Serum-Free Iterative Rabies Vaccine Has Received Production License and Will Submit for Market Registration

Launch of Major Product Expected to Significantly Drive Performance Growth HONG KONG, March 12, 202...

2025-03-12 07:53 2137

AIM Vaccine's Iteratively Upgraded Diploid Rabies Vaccine Approved for Clinical Trials, Showing Significantly Higher Efficacy than Marketed Diploid Rabies Vaccines

HONG KONG, March 10, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine c...

2025-03-10 08:00 3345

AIM Vaccine's mRNA RSV Vaccine Approved for U.S. Clinical Trials

Innovation and Global Expansion Attract Capital Reassessment AIM Vaccine Co., Ltd. (a joint stock ...

2025-02-27 08:00 4008

AIM Vaccine's mRNA Shingles Vaccine Submits Clinical Application to the U.S.

Another Step Forward in Global Expansion HONG KONG, Feb. 25, 2025 /PRNewswire/ -- As global capital...

2025-02-25 08:00 1956

AIM Vaccine Integrates DeepSeek: Innovative Technology and Growth Potential Support Valuation Upside

HONG KONG, Feb. 24, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine co...

2025-02-24 11:20 2194

AIM Vaccine Leverages AI to Advance mRNA Vaccine Development mRNA Shingles Vaccine Submits Clinical Trial Application

HONG KONG, Feb. 12, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine co...

2025-02-12 13:15 2802

Guangdong Land Announced 2023 Annual Results

Steady improvement in both quality and quantity of property delivery in the Greater Bay Area HONG ...

2024-03-27 23:49 6597

Beauty Farm Issues Positive Profit Alert for 2023

HONG KONG, Feb. 2, 2024 /PRNewswire/ -- Beauty Farm Medical and Health Industry Inc. ("Beauty Farm"...

2024-02-02 19:43 6694